Pipeline Overview

Genosco’s current pipeline consists of three assets in the clinical stage, and two assets
in the pre-clinical stage. Our core competence comes from its know-how in generating selective
kinase inhibitor of interest.
  • Lazertinib (GNS-1480), an EGFR mutant-selective inhibitor for non-small cell lung cancer
    (NSCLC) and its metastatic brain cancer, is in clinical phase 3 study. This program is our most
    advanced pipeline and has been licensed out to Yuhan Corporation.
  • SKI-O-703, a selective SYK inhibitor for rheumatoid arthritis (RA), and idiopathic thrombocytopenic
    purpura (ITP), is in clinical phase 2 study.
  • SKI-G-801, an FLT3 inhibitor for acute myeloid leukemia is in clinical phase 1 study.
  • FGFR4 program for hepatocellular carcinoma is in the lead optimization stage. This
    program has been licensed out to Yuhan Corporation.
  • ROCK2 and FGFR2/3 programs are in the lead optimization stage.

    • Proprietary Pipeline

    Discovery Lead Opt Preclinical Phase I Phase II Phase III
    SKI-O-703(RA)
    SKI-O-703(ITP)
    SKI-G-801(AML)
    ROCK2 Program
    FGFR2/3 Program

    Collaborative Pipeline

    Discovery Lead Opt Preclinical Phase I Phase II Phase III
    Lazertinib:GNS-1480(NSCLC)
    4th Gen EGFR inhibitor(NSCLC)
    FGFR4 inhibitor(HCC)